Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-07-17 pm EDT			5-day change	1st Jan Change
7.62 ^USD	+0.93%		+4.10%	-4.99%

Jul. 10	Raymond James Initiates Bausch Health at Market Perform Rating	MT
Jun. 21	Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	MT

Bausch Health Launches $1 Billion Senior Secured Notes Offering

January 27, 2022 at 08:34 am EST

By Adriano Marchese

Bausch Health Cos. Inc. said Thursday that it plans to raise $1 billion by way of a senior secured notes offering.

The Canadian specialty pharmaceutical company said it will use the proceeds toward the redemption of its outstanding 6.125% senior notes due in 2025, to refinance all of its existing Term B loans, as well as fund partial redemption of other outstanding senior notes.

The new senior secured notes being offered are due in 2027.

The company is seeking to refinance its existing credit agreement, which is expected to occur after completing the spinoff of Bausch + Lomb Corp.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

01-27-22 0834ET

Latest news about Bausch Health Companies Inc.

Raymond James Initiates Bausch Health at Market Perform Rating	Jul. 10	MT
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	Jun. 21	MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	Jun. 17	MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	Jun. 03	MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	May. 28	MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	May. 23	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	May. 17	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	May. 15	MT
Bausch Health Companies Inc. Approves Directorate Appointments	May. 15	CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	May. 14	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	May. 14	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	May. 13	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	May. 03	MT
Bausch Health Shares Fall Following Q1 Results	May. 02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	May. 02	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	May. 02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	May. 02	MT
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	May. 02	CI
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Company Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.62 USD

Average target price

9.562 USD

Spread / Average Target

+25.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-4.99%	2.75B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+31.64%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+15.51%	247B
NOVARTIS AG	+16.72%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Pharmaceuticals

Bausch Health Launches $1 Billion Senior Secured Notes Offering

EPS Revisions